
# PRINTER RUSH (PTO ASSISTANCE)

Application :	09/542,5 NPB	Examiner: _	LUNZ  IDC) FMF FDC	GAU :	11/10/04
	IFWLE)	Tracking #:		Week Date:	4/19/04
	DOC CODE  1449  1DS CLM IIFW SRFW DRW OATH 312 SPEC	DOC DATE	MISCELL Continuing Foreign Price Document I Fees Other	Data ority Legibility	
RUSH] MESS	(i) Please Ve bibskeet	offy relationships shows "CONTING not be updated - e	MON" Kextrea		l NO 03/942.59 ADON IN-JUNET" Huntyp
KRUSH] RES	PONSE:	TOTO SOLL V	- September 1891	100 to 11.00	

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

REV 10/04

**INITIALS:** 





COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231 www.uspta.gov

SERIAL NUMBER 09/542,520	FILING DATE 04/03/2000 RULE _	·	CLASS 530	GROUP ART 1646		I UNIT		ATTORNEY OCKET NO. 1969-076-999			
APPLICANTS  W. James Jackson, Marriottsville, MD;  John L. Pace, Germantown, MD;											
THIS APPLICATION IS A CON OF PCT/US98/20737 10/01/1998 WHICH IS A CON OF 08/942,596 10/02/1997											
** FOREIGN APPLICATIONS ************************************											
IF REQUIRED, FOREIGN FILING LICENSE  GRANTED ** 06/16/2000											
Foreign Priority claimed  35 USC 119 (e-d) conditions met Verified and Acknowledged	er tials	STATE OR COUNTRY MD	SHEETS DRAWING 11		TOTAL CLAIMS 61		INDEPENDENT CLAIMS 6				
Acknowledged Examiner's Signature Initials  ADDRES'S  _ 20583											
TITLE			-								
Chlamydia protein, ç	gene sequence and use:	s thereof	f					<del></del>			
RECEIVED No.	S: Authority has been given in Paper to charge/credit DEPOST ACCOUNT for following:				All Fees  1.16 Fees (Filing)  1.17 Fees (Processing Ext. of time)  1.18 Fees (Issue)  Other  Credit						

BI

This application is a continuation of PCT/US98/20737 filed October 1, 1998 which is a continuation-in-part of U.S. Patent Application No. 08/942,596 filed October 2, 1997.

## IN THE CLAIMS:

Please cancel non-elected claims 1,20, 23,31 and 38-41 without prejudice.

ŗ

Please amend 21, 32, 33, 35-37 to read as set forth below:

R1

21. (Once Amended) A method of producing an immune response in an animal comprising administering to said animal an effective amount of an antigenic composition comprising an isolated *Chlamydia* species high molecular weight (HMW) protein wherein the apparent molecular weight is about 105-115 kDa, as determined by sodium dodecylsulfate-polyacrylamide gal electrophoresis (SDS-PAGE), wherein the *Chlamydia* species is *Chlamydia* trachomatis, *Chlamydia* pecorum, or *Chlamydia* pneumoniae, or an analogue of the HMW protein wherein the analogue has an apparent molecular weight of about 105-115 kDa, as determined by SDS-PAGE and is recognizable by an antibody that specifically binds to a peptide comprising an amino acid sequence of SEQ ID No. 2, 15 or 16.

<sub>1</sub>R2

disorder related to Chlamydia in a host in need thereof comprising administering to a host, an effective amount of a pharmaceutical composition or vaccine composition comprising an isolated Chlamydia species high molecular weight (HMW) protein wherein the apparent molecular weight is about 105-115 kDa, as determined by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS PRGE), wherein the Chlamydia species is Chlamydia trachomatis, Chlamydia pecorum or Chlamydia pneumoniae, or an analogue of the HMW protein wherein the analogue has an apparent molecular weight of about 105-115 kDa, as determined by SDS-PAGE and is recognizable by an antibody that specifically binds to a peptide comprising an amino acid sequence of SEQ ID No. 2, 15 or 16 or a fragment of said HMW wherein the fragment is recognizable by an antibody that specifically binds to a peptide comprising an amino acid sequence of SEQ ID No. 2, 15 or 16 or a recombinant protein comprising a Chlamydia protein and a leader sequence, wherein the apparent